Biotech | January 20, 2026
DNA Nanorobots & AI could slash drug development times, Nanovery CEO says
DNA nanorobots—tiny, self-assembling machines capable of detecting diseases in blood samples within 2–4 hours
DNA nanorobots—tiny, self-assembling machines capable of detecting diseases in blood samples within 2–4 hours
Favorable outcome would contribute to significantly containing the Roundup litigation as the company continues its multi-pronged strategy
ATEC secures exclusive U.S. commercial rights to Theradaptive’s OsteoAdapt osteoinductive bone graft, currently in clinical trials for spinal and dental applications
Approval marks Venus Remedies’ first anti-infective marketing authorization in Indonesia and enables the country’s first generic entry for this critical antibiotic combination
The deal to acquire AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) underscores Bayer’s commitment to expanding in molecular imaging and advancing precision cardiology
The BD Neopak Glass Prefillable Syringe platform is designed for the complex needs of biologics and combination products
The acquisition of AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) positions Bayer at the forefront of cardiac amyloidosis diagnostics
AbbVie will offer reduced prices for its medicines in Medicaid and commit $100 billion over the next decade to US research, development and capital investments, including domestic manufacturing
Supports production of AbbVie's current and next-generation immunology and neuroscience medicines
Subscribe To Our Newsletter & Stay Updated
